Aller au contenu principal
Accès ouvert déclaré 2025 article

A Rash Decision: Implementing an EHR-Integrated Penicillin Allergy Delabeling Protocol without Adequate Clinician Support

1Citations signalées, ce qui n’est pas une note de qualité
6Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : us. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Approximately 10% of patients have a documented penicillin "allergy"; however, up to 95% have subsequent negative testing. These patients may receive suboptimal antibiotics, leading to longer hospitalizations and higher costs, rates of resistant and nosocomial infections, and all-cause mortality. To mitigate these risks in children, we implemented an inpatient penicillin allergy delabeling protocol and integrated it into the electronic health record (EHR) through a mixed methods approach of clinical decision support (CDS).We describe our protocol implementation across three sequential phases: "Pilot," "Active Antimicrobial Stewardship Program (ASP)," and "Mixed CDS." We highlight several potential pitfalls that may have contributed to poor clinician adoption.Patients were risk-stratified as nonallergic, low-risk, or high-risk based on history. Process measures included: evaluation rate, oral challenge rate for low-risk, and allergy referral rate for high- or low-risk when oral challenge was deferred. The primary outcome measure was the penicillin allergy delabeling rate among low-risk or nonallergic. Balancing measures included the rate of epinephrine or antihistamine administrations.The pilot and ASP phases used clinician education and an order set, but were mostly manual processes. The mixed CDS phase introduced interruptive alerts, dynamic text in note templates, and patient list columns to guide clinicians, but little education was provided. The mixed CDS phase had the lowest evaluation rate compared with the pilot and active ASP phases (6.4 vs. 25 vs. 15%). However, when the evaluation was performed, the mixed CDS phase had the highest oral challenge rate (33 vs. 26 vs. 13%) and delabeling rate (43 vs. 33 vs. 27%). No adverse events occurred.CDS tools improve clinician decision-making and optimize patient care. However, relying on CDS for complex clinical evaluations can lead to failure when clinicians cannot find the tool or appreciate its importance. Person-to-person communication can be vital in establishing a process and educating intended users for successful CDS implementation.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
A Rash Decision: Implementing an EHR-Integrated Penicillin Allergy Delabeling Protocol without Adequate Clinician Support
Date Crossref
28/04/2025
Éditeur
Georg Thieme Verlag KG
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Pharmacovigilance and Adverse Drug ReactionsAntibiotic Use and ResistanceDrug-Induced Adverse Reactions

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.